COMPENSATION AND BENEFITS 15 15.3.5 FREE SHARES AVAILABLE IN 2017 The following free shares became available during the fiscal year ended December 31, 2017. Name Grant Date Number of Shares Granted Number of shares which became Performance Criteria available during the exercise Bernard Gilly 07/26/2016 250,000 125,000 (1) (1) 50% of AGA 2016 were acquired at the completion of enrollment in RESCUE and REVERSE clinical trials on 07/27/2017. 15.4 HISTORY OF ALLOCATION OF SHARE WARRANTS, SHARE WARRANTS FOR FOUNDERS AND STOCK OPTIONS Table 8 (AMF definition) 15.4.1 HISTORY OF SHARE WARRANTS FOR FOUNDERS (BCE) BCE Issued BCE Issued BCE Issued BCE Issued July 2013 April 2014 December 2014 July 2015 Date of shareholders’ meeting 02/05/2013 02/05/2013 06/25/2014 06/29/2015 Date of allocation by the Board of 07/08/2013 04/09/2014 12/03/2014 07/08/2015 Directors Total number of BCE authorized 2,334,959 2,334,959 2,334,959 856,000 Total number of BCE granted 892,000 193,800 60,000 733,298 Including those granted to Mr. Gilly 300,000 — — 161,000 Including those granted to Mr. Wyzga — — — — Start date for the exercise of the BCE 07/08/2013 04/08/2014 12/03/2014 07/08/2015 BCE expiry date 07/07/2023 04/07/2024 12/02/2024 07/07/2025 BCE exercise price €0.025 €0.025 €0.025 €3.275 Number of shares subscribed 768,280 193,800 — 71,765 as of March 31, 2018 Total number of BCE canceled or — — — 147,618 obsolete as of March 31, 2018 Total number of BCE outstanding 123,720 — 60,000 513,916 as of March 31, 2018 Total number of shares available 123,720 — 60,000 513,916 for subscription as of March 31, 2018 GENSIGHT BIOLOGICS – 2017 Registration Document– 161